Interferon Lambda as a Potential New Therapeutic for Hepatitis C
Interferon Lambda as a Potential New Therapeutic for Hepatitis C
复制标题
DOI：
10.1111/j.1749-6632.2009.05241.x
复制
发表时间：
2009-01-01
期刊：
影响因子：
--
通讯作者：
Williams, Doug E.
中科院分区：
文献类型：
--
作者：
Miller, Dennis M.;Klucher, Kevin M.;Williams, Doug E.
干扰素（ifn - γ）是具有生物活性的III型干扰素，包括诱导抗病毒基因，类似于I型干扰素，但通过不同的受体复合物发出信号。ifn - γ受体的表达模式比广泛分布的ifn - α受体更具细胞特异性，这表明在体内，ifn - γ可能比ifn - α具有更少的副作用，例如更少的血液学毒性。ifn -的聚乙二醇化形式。（PEG-rIL-29）在动物中耐受性良好，不会导致血液毒性。PEG-rIL-29初步研究的临床数据表明，它对丙型肝炎患者具有抗病毒作用，但不会产生血液毒性。这些临床前和早期临床数据支持PEG-rIL-29作为治疗丙型肝炎患者的潜在新治疗剂。
Interferon lambdas (IFN-gamma) are Type III interferons with biological activity, including induction of antiviral genes, similar to Type I IENs, but signal through a distinct receptor complex. The expression pattern for the IFN-gamma receptor is more cell specific than the widely distributed IFN-alpha receptor, suggesting in vivo, IFN-gamma may have fewer side effects than IFN-alpha, such as less hematologic toxicities. A PEGylated form of IFN-gamma. (PEG-rIL-29) was well tolerated in animals and did not result in hematologic toxicity. Clinical data from initial studies of PEG-rIL-29 has demonstrated antiviral effects in patients with hepatitis C without producing hematologic toxicity. These preclinical and early clinical data support PEG-rIL-29 as a potential new therapeutic agent for treatment of patients with hepatitis C.